Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde) (irinotecan hydrochloride) is a small molecule pharmaceutical. Irinotecan hydrochloride was first approved as Camptosar on 2016-10-14. It is used to treat breast neoplasms, colonic neoplasms, leukemia, lymphoma, and neoplasm metastasis amongst others in the USA. It has been approved in Europe to treat pancreatic neoplasms. The pharmaceutical is active against DNA topoisomerase 1. Camptosar's patents are valid until 2036-10-15 (FDA).
|Trade Name||Onivyde pegylated liposomal (previously known as Onivyde)|
|Common Name||Irinotecan hydrochloride trihydrate|
|Indication||breast neoplasms, colonic neoplasms, leukemia, lymphoma, neoplasm metastasis, non-small-cell lung carcinoma, pancreatic neoplasms, rectal neoplasms, stomach neoplasms|
|Drug Class||Antineoplastics (camptothecine derivatives)|